BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30629142)

  • 1. Genetic variability of the ABCC2 gene and clinical outcomes in pancreatic cancer patients.
    Gentiluomo M; Puchalt García P; Galeotti AA; Talar-Wojnarowska R; Tjaden C; Tavano F; Strobel O; Kupcinskas J; Neoptolemos J; Hegyi P; Costello E; Pezzilli R; Sperti C; Lawlor RT; Capurso G; Szentesi A; Soucek P; Vodicka P; Lovecek M; Hackert T; Cavestro GM; Milanetto AC; Canzian F; Campa D
    Carcinogenesis; 2019 Jun; 40(4):544-550. PubMed ID: 30629142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single nucleotide polymorphism in the microRNA-199a binding site of HIF1A gene is associated with pancreatic ductal adenocarcinoma risk and worse clinical outcomes.
    Wang X; Ren H; Zhao T; Ma W; Dong J; Zhang S; Xin W; Yang S; Jia L; Hao J
    Oncotarget; 2016 Mar; 7(12):13717-29. PubMed ID: 26872370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation.
    Campa D; Pastore M; Capurso G; Hackert T; Di Leo M; Izbicki JR; Khaw KT; Gioffreda D; Kupcinskas J; Pasquali C; Macinga P; Kaaks R; Stigliano S; Peeters PH; Key TJ; Talar-Wojnarowska R; Vodicka P; Valente R; Vashist YK; Salvia R; Papaconstantinou I; Shimizu Y; Valsuani C; Zambon CF; Gazouli M; Valantiene I; Niesen W; Mohelnikova-Duchonova B; Hara K; Soucek P; Malecka-Panas E; Bueno-de-Mesquita HBA; Johnson T; Brenner H; Tavano F; Fogar P; Ito H; Sperti C; Butterbach K; Latiano A; Andriulli A; Cavestro GM; Busch ORC; Dijk F; Greenhalf W; Matsuo K; Lombardo C; Strobel O; König AK; Cuk K; Strothmann H; Katzke V; Cantore M; Mambrini A; Oliverius M; Pezzilli R; Landi S; Canzian F
    Int J Cancer; 2018 Jan; 142(2):290-296. PubMed ID: 28913878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl peptidase like 6 promoter methylation is a potential prognostic biomarker for pancreatic ductal adenocarcinoma.
    Zhao X; Cao D; Ren Z; Liu Z; Lv S; Zhu J; Li L; Lang R; He Q
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32701143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
    Zhao L; Zhao H; Yan H
    BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of replication of seven pancreatic cancer susceptibility loci identified in two Asian populations.
    Campa D; Rizzato C; Bauer AS; Werner J; Capurso G; Costello E; Talar-Wojnarowska R; Jamroziak K; Pezzilli R; Gazouli M; Khaw KT; Key TJ; Bambi F; Mohelnikova-Duchonova B; Heller A; Landi S; Vodickova L; Theodoropoulos G; Bugert P; Vodicka P; Hoheisel JD; Delle Fave G; Neoptolemos JP; Soucek P; Büchler MW; Giese N; Canzian F
    Cancer Epidemiol Biomarkers Prev; 2013 Feb; 22(2):320-3. PubMed ID: 23250936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer.
    Schirmer MA; Lüske CM; Roppel S; Schaudinn A; Zimmer C; Pflüger R; Haubrock M; Rapp J; Güngör C; Bockhorn M; Hackert T; Hank T; Strobel O; Werner J; Izbicki JR; Johnsen SA; Gaedcke J; Brockmöller J; Ghadimi BM
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26857392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD44 SNPrs187115: A Novel Biomarker Signature that Predicts Survival in Resectable Pancreatic Ductal Adenocarcinoma.
    Stracquadanio G; Vrugt B; Flury R; Schraml P; Würl P; Müller TH; Knippschild U; Henne-Bruns D; Breitenstein S; Clavien PA; Graf R; Bond GL; Grochola LF
    Clin Cancer Res; 2016 Dec; 22(24):6069-6077. PubMed ID: 27283965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 15-Inflammation-Related Gene Signature Predicts the Prognosis of Patients With Pancreatic Ductal Adenocarcinoma.
    Sun X; Song H; Sun X; Liao C; Wang G; Xu Y; Li L; Han Y; Xu C; Wang W; Cai S; Liang H; Yu H
    Cancer Invest; 2024 Mar; 42(3):226-242. PubMed ID: 38616304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KIAA1199/CEMIP/HYBID overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
    Koga A; Sato N; Kohi S; Yabuki K; Cheng XB; Hisaoka M; Hirata K
    Pancreatology; 2017; 17(1):115-122. PubMed ID: 28012880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
    Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
    Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
    JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients.
    Lee SH; Kim H; Hwang JH; Lee HS; Cho JY; Yoon YS; Han HS
    Pathol Int; 2012 Mar; 62(3):167-75. PubMed ID: 22360504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival.
    Gentiluomo M; Corradi C; Vanella G; Johansen AZ; Strobel O; Szentesi A; Milanetto AC; Hegyi P; Kupcinskas J; Tavano F; Neoptolemos JP; Bozzato D; Hackert T; Pezzilli R; Johansen JS; Costello E; Mohelnikova-Duchonova B; van Eijck CHJ; Talar-Wojnarowska R; Hansen CP; Darvasi E; Chen IM; Cavestro GM; Soucek P; Piredda L; Vodicka P; Gazouli M; Arcidiacono PG; Canzian F; Campa D; Capurso G
    Sci Rep; 2021 Apr; 11(1):7570. PubMed ID: 33828170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
    Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
    Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma.
    Kandimalla R; Tomihara H; Banwait JK; Yamamura K; Singh G; Baba H; Goel A
    Clin Cancer Res; 2020 Jul; 26(14):3641-3648. PubMed ID: 32234757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of long non-coding RNA LOC285194 and its prognostic significance in human pancreatic ductal adenocarcinoma.
    Ding YC; Yu W; Ma C; Wang Q; Huang CS; Huang T
    Int J Clin Exp Pathol; 2014; 7(11):8065-70. PubMed ID: 25550852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
    Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
    World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and comparative outcomes of periampullary cancer: A population-based analysis demonstrating improved outcomes and increased use of adjuvant therapy from 2004 to 2012.
    Hester CA; Dogeas E; Augustine MM; Mansour JC; Polanco PM; Porembka MR; Wang SC; Zeh HJ; Yopp AC
    J Surg Oncol; 2019 Mar; 119(3):303-317. PubMed ID: 30561818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.